WallStSmart

Abbott Laboratories (ABT)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 119% more annual revenue ($46.59B vs $21.27B). ABT leads profitability with a 11.7% profit margin vs 9.3%. GEHC appears more attractively valued with a PEG of 1.88. GEHC earns a higher WallStSmart Score of 65/100 (C+).

ABT

Buy

52

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

GEHC

Buy

65

out of 100

Grade: C+

Growth: 6.0Profit: 6.5Value: 5.7Quality: 4.5
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$73.35

Current Price

$105.64

$32.29 premium

UndervaluedFair: $73.35Overvalued

Intrinsic value data unavailable for GEHC.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$177.07B9/10

Large-cap with strong market position

GEHC2 strengths · Avg: 8.0/10
P/E RatioValuation
15.7x8/10

Attractively priced relative to earnings

Price/BookValuation
3.0x8/10

Reasonable price relative to book value

Areas to Watch

ABT3 concerns · Avg: 3.3/10
PEG RatioValuation
2.014/10

Expensive relative to growth rate

P/E RatioValuation
32.2x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-47.5%2/10

Earnings declined 47.5%

GEHC3 concerns · Avg: 3.0/10
PEG RatioValuation
1.884/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. Revenue growth of 13.0% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on P/E Ratio, Price/Book.

Bear Case : ABT

The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, Altman Z-Score.

Key Dynamics to Monitor

GEHC carries more volatility with a beta of 0.84 — expect wider price swings.

ABT is growing revenue faster at 13.0% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GEHC scores higher overall (65/100 vs 52/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?